PresentationPresentation Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML) PDF (1.24 MB) Read MorePresentation Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM) PDF (3.12 MB) Read MorePresentation A first-in-class, first-in-human Phase I trial of KPT-330, a Selective Inhibitor of Nuclear Export (SINE) in patients (pts) with advanced solid tumors PDF (2.94 MB) Read MorePresentation Targeted inhibition of Chromosomal Maintenance Region Protein (CRM1) potently suppresses growth of human neuroblastoma cell line models PDF (1.41 MB) Read MorePresentation Results of a Phase I Dose Escalation Study of the Novel, Oral CRM1 Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Dogs with Spontaneous Non-Hodgkin’s Lymphomas (NHL) ()Presentation Potent anticancer activity against both BRAF-mutant and BRAF wild-type melanoma cell lines using a novel CRM1 nuclear export inhibitor PDF (1.40 MB) Read MorePresentation KPT-0127 Induces Selective Apoptosis of Malignant Cells by CRM1 Inhibition and Elevation of Regulatory Proteins p53, p21, FOXO and IkB PDF (1.24 MB) Read MorePresentation KPT-0127, a Novel, Potent and Selective Inhibitor of CRM1-Mediated Nuclear Export Shows Selective Cytotoxicity for the Treatment of Hematological Cancers PDF (1.17 MB) Read More Previous 1 … 13 14 15